Research programme: microRNA therapeutics - Microlin Bio

Drug Profile

Research programme: microRNA therapeutics - Microlin Bio

Alternative Names: Colomiralin™; Lumiralin™; miR 17 5p inhibitor - Microlin Bio; miR 17 inhibitors - Microlin Bio; miR 21 inhibitor - Microlin Bio; miR 484 inhibitor - Microlin Bio; Omiralin™; Promiralin™

Latest Information Update: 14 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ohio State University
  • Developer Microlin Bio; Ohio State University
  • Class Antisense oligonucleotides; MicroRNAs; Oligonucleotides
  • Mechanism of Action MicroRNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Lung cancer

Most Recent Events

  • 12 Jan 2016 Preclinical data released by Microlin Bio
  • 24 Sep 2015 Research programme: microRNA therapeutics - Microlin Bio is available for licensing as of 24 Sep 2015.
  • 24 Sep 2015 Preclinical trials in Lung cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top